New
HealthMore in Health→
Exosome Liquid Biopsy Targets Early Pancreatic Cancer in 1,785-Person Study
Key Takeaways
- Nature Medicine published the study online on 16 September 2026 under DOI 10.1038/s41591-026-04625-x.
- The prospective study enrolled 1,785 individuals from four countries.
- It evaluated PANXEON, described as an exosome-based biomarker, for early detection of pancreatic ductal adenocarcinoma.
- The publicly available summary text is truncated, so sensitivity and specificity figures could not be verified from the metadata.
DE
DT Editorial Team··via nature.com